Are dark clouds rolling in on TIGIT?

Often times we see a press release for a negative trial – defined here as one which missed its primary endpoint – where the overwhelming temptation is to simply announce the top level findings and be done with it.

I will argue there are valuable lessons to be learned in the process, and sometimes, perhaps realise a different trial design or selection criteria might have led to an entirely different result.

Here is one example I’d like to highlight because phase 3 trials are already underway and there may be insights we can learn from and handicap future larger trial readouts…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by